



To learn more, visit www.ipox.com;
 Email: info@ipox.com
 Office: +1 (312) 526-3634
 Support +1 (312) 339-4114

MYOKARDIA MYOKARDIA, INC (MYOK US)

COMPANY DESCRIPTION

Incorporated in 2012, **MyoKardia** is a South San Francisco, CA-based clinical-stage biopharmaceutical company specializes in precision medicine with a focus on treatment of serious cardiovascular diseases.

BUSINESS MODEL


MyoKardia has not generated any revenue from product sales since inception. The company generated revenue solely from the exclusive collaboration and license arrangement with Sanofi, via its subsidiary (agreement terminated in December 2018). MyoKardia had not generated any revenues after December 31, 2018. The company currently relies on private and public equity financing to fund its operations.

IPO HISTORY


On **10/29/2015**, MyoKardia began trading on Nasdaq led by Credit Suisse and Cowen & Co. The biopharmaceutical company upsized to sell 5,437,500 shares at **\$10.00 per share**, below its expected price range (\$15 to \$17). With the 15% greenshoe options fully exercised, the heart drug developer was valued at ca. \$262 million at offer. The shares opened at \$11.80/share and closed the first day down at \$10.53 (▲5.30%).

MyoKardia was included in the IPOX® 100 U.S. Portfolio (ETF: FPX) on 9/20/2019 and currently weighs ca. 0.45% of the portfolio. On 10/5/2020, Bristol-Myers Squibb announced to acquire MyoKardia for \$13.1 billion, or \$225.00/share in cash, a premium of 61% over the previous close.

HISTORICAL PERFORMANCE



GROWTH OUTLOOK



Pipeline	Program	Indication	Stage
Hypertrophic Cardiomyopathy	Mavacamten*	Obstructive HCM	Phase 3
		Non-obstructive HCM	Phase 2
		Precision diastolic disease (HFpEF)	
Diastolic Heart Failure	MYK-224	HCM	Phase 1
Systolic Heart Failure	LUS-1	Precision Diastolic Disease(s)	Preclinical
	Danicamtiv	Genetic dilated cardiomyopathy (DCM)	Phase 2
		ACT-1	Precision Systolic Diseases

* A New Drug Application ("NDA") for mavacamten for the treatment of symptomatic obstructive HCM is expected to be submitted to the U.S. FDA in Q1 2021.

INDUSTRY COMPARISON

Company	Stock Symbol	IPO/Spin-off Date	Initial Return	Offer to Date	2020 YTD	Beta to Benchmark	Revenues In millions	Earnings (Losses)/share
MYOKARDIA	MYOK US	10/29/2015	5.30%	2110.00%	203.18%	0.76	0.00	-\$6.17
Cytokinetics	CYTK US	4/28/2004	23.85%	-63.32%	168.80%	1.11	26.87	-\$2.11

Other multinational large competitors include Amgen Inc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Eli Lilly and Company, Novartis AG, Takeda Pharmaceutical Company Limited, and Pfizer Inc.